Impact of Anti-drug Antibodies in Patients with Fabry Disease under Enzyme Replacement Therapy: Long-Term Outcomes

Malte Lenders, Elisa Rudolph, Robert Radke, Peter Nordbeck, Eva Brand

Open source

DOI
10.1007/s40259-026-00817-6
Published
2026-11-04
Container
BioDrugs
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s40259-026-00817-6,
  title = {Impact of Anti-drug Antibodies in Patients with Fabry Disease under Enzyme Replacement Therapy: Long-Term Outcomes},
  author = {Malte Lenders and Elisa Rudolph and Robert Radke and Peter Nordbeck and Eva Brand},
  year = {2026},
  journal = {BioDrugs},
  doi = {10.1007/s40259-026-00817-6},
  url = {https://doi.org/10.1007/s40259-026-00817-6}
}

RIS

TY  - JOUR
TI  - Impact of Anti-drug Antibodies in Patients with Fabry Disease under Enzyme Replacement Therapy: Long-Term Outcomes
AU  - Malte Lenders
AU  - Elisa Rudolph
AU  - Robert Radke
AU  - Peter Nordbeck
AU  - Eva Brand
PY  - 2026
JO  - BioDrugs
DO  - 10.1007/s40259-026-00817-6
UR  - https://doi.org/10.1007/s40259-026-00817-6
ER  - 

APA

Lenders, M., Rudolph, E., Radke, R., Nordbeck, P., & Brand, E. (2026). Impact of Anti-drug Antibodies in Patients with Fabry Disease under Enzyme Replacement Therapy: Long-Term Outcomes. BioDrugs. https://doi.org/10.1007/s40259-026-00817-6

Source records